AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 288: H914-H922, 2005. First published October 14, 2004; doi:10.1152/ajpheart.00465.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H914    most recent
00465.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tachibana, H.
Right arrow Articles by Cheng, C.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tachibana, H.
Right arrow Articles by Cheng, C.-P.

Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure

Hideo Tachibana, Heng-Jie Cheng, Tomohiko Ukai, Akihiko Igawa, Zhu-Shan Zhang, William C. Little, and Che-Ping Cheng

Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Submitted 18 May 2004 ; accepted in final form 30 September 2004


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The new myofilament Ca2+ sensitizer levosimendan (LSM) is a positive inotropic and vasodilatory agent. Its beneficial effects have been demonstrated at rest in congestive heart failure (CHF). However, its effect during exercise (Ex) in CHF is unknown. We assessed the effects of LSM on left ventricular (LV) dynamics at rest and during Ex in eight conscious, instrumented dogs with pacing-induced CHF. After CHF, with dogs at rest, LSM decreased arterial elastance (Ea) and increased LV contractile performance as assessed by the slope of LV pressure-volume (P-V) relation. LSM caused a >60% increase in the peak rate of mitral flow (dV/dtmax) due to decreases in minimal LV pressure and the time constant of LV relaxation ({tau}). LV arterial coupling, quantified as the ratio of end-systolic elastance (Ees) to Ea, was increased from 0.47 to 0.85%. LV mechanical efficiency, determined as the ratio of stroke work to total P-V area, was improved from 0.54 ± 0.09 to 0.61 ± 0.07. These beneficial effects persisted during Ex after CHF. Compared with CHF Ex dogs, treatment with LSM prevented Ex-induced abnormal increases in mean left atrial pressure and end-diastolic pressure and decreased Ees/Ea. With LSM treatment during CHF Ex, the early diastolic portion of the LV P-V loop was shifted downward with decreased minimal LV pressure and {tau} values and a further augmented dV/dtmax. Ees/Ea improved, and mechanical efficiency further increased from 0.61 ± 0.07 to 0.67 ± 0.07, which was close to the value reached during normal Ex. After CHF, LSM produced arterial vasodilatation; improved LV relaxation and diastolic filling; increased contractility, LV arterial coupling, and mechanical efficiency; and normalized the response to Ex.

congestive heart failure; left ventricular dynamics; filling; contractility; mechanical efficiency

IMPORTANT GOALS IN THE TREATMENT of patients with congestive heart failure (CHF) are to prolong survival and improve the patient's quality of life. The major symptom and cause of disability in CHF patients is exercise (Ex) intolerance (5, 32, 45). Observational work in the general healthy population has shown that Ex capacity is a more powerful prognostic indicator than traditional risk factors for cardiovascular disease (36, 44). However, despite enormous advances in the understanding and treatment of CHF that have taken place during the last 50 years, CHF remains a serious and, in fact, growing health problem. Present treatment of Ex intolerance is unsatisfactory in CHF patients (45, 63). The {beta}-adrenergic agonist dobutamine and phosphodiesterase inhibitor milrinone were associated with worse survival and clinical outcomes and did not improve quality of life for severe CHF patients (42, 48). Angiotensin-converting enzyme inhibitor therapy and {beta}-blockade treatment improve survival in patients with CHF but do not always enhance Ex tolerance (37). Recently myofilament Ca2+ sensitizers, which are a new class of nonglycosidic, nonadrenergic, positive inotropic agents, have been studied in patients with CHF. Because impaired relaxation often accompanies systolic dysfunction (5, 18, 32, 45), enhanced Ca2+ sensitivity might have negative effects with increased sensitivity to Ca2+ during diastole, thereby further slowing relaxation and worsening diastolic dysfunction (22). Such prolonged relaxation impairing diastolic function has been observed with the Ca2+ sensitizers EMD-57033 and -53998, ORG-30029, and CGP-48506 (19, 22, 26, 64). Both EMD-57033 (without phosphodiesterase inhibition properties) and ORG-30029 (with phosphodiesterase inhibition properties) impaired relaxation to a greater extent in failing than nonfailing human hearts (22).

The limitation of Ex tolerance in CHF results from both cardiac and peripheral factors (45). The exacerbation of diastolic dysfunction during CHF Ex and the resulting increase in left atrial pressure (LAP) contribute to exertional dyspnea. Observations in our laboratory demonstrate that there is a reversal of the normal Ex-induced augmentation of left ventricular (LV) relaxation and a decrease in early diastolic LV pressure (LVP) with a resulting rise in LAP (9, 10). We found that before CHF, the effect of an Ex-induced increase in systolic load alone slows the rate of LV relaxation. However, this effect is overcome during normal Ex by sympathetic stimulation and increased heart rate, which enhance the rate of LV isovolumic pressure decrease. After CHF, the Ex-induced increase in systolic load persists, but the effects of increased heart rate and {beta}-adrenergic stimulation to speed relaxation are reduced. In addition, both ANG II and endothelin-1 increase to very high levels. Thus LV relaxation slows, and LV end-systolic volume (ESV) and minimum pressure (LVPmin) increase. The early diastolic portion of the LV pressure-volume (P-V) loop shifts upward and rightward during Ex after CHF. Thus any diastolic dysfunction present at rest in CHF is exacerbated during Ex (8, 11).

Levosimendan (LSM), a novel Ca2+ sensitizer, is reported to be an inotropic and vasodilator agent without adverse effects on diastolic function (24, 43, 48, 61, 62). Unlike most other Ca2+ sensitizers, LSM acts through direct binding with troponin C and increases the affinity of troponin C for Ca2+ in a Ca2+-dependent manner. A lack of Ca2+ sensitization under low Ca2+ concentrations (i.e., during diastole) may prevent worsening of diastolic dysfunction. The phosphodiesterase III inhibitory component may possibly exert a positive effect on the rate of relaxation (14, 20). In recent clinical trials, intravenous administration of LSM produced a dose-dependent favorable hemodynamic effect in the acute treatment of stable or decompensated CHF (38, 48). LSM improved the survival of patients with severe low-output CHF (15). In addition, LSM reduced the risks of worsening CHF and death in patients with CHF (35, 62). Although beneficial effects of LSM in CHF at rest have been demonstrated, its effects during Ex are not known.

The present study tests the hypothesis that LSM, a pyridazinone-dinitrile derivative with phosphodiesterase III inhibitory properties, may improve both LV systolic and diastolic performance at rest and normalize Ex response after CHF. Studies were performed on a conscious, instrumented dog model with pacing-induced CHF that shares many of the structural hemodynamic and neurohormonal changes seen in human CHF (5, 9, 10, 32).

Our results provide insight into a mechanism of Ex intolerance in CHF and suggest a therapeutic strategy to enhance Ex performance in CHF patients.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Instrumentation

This investigation was approved by the Institutional Animal Care and Use Committee. Eight healthy, adult, heartworm-negative mongrel dogs (body wt, 25–35 kg) were instrumented to measure three LV internal dimensions, LVP, and LAP. Hydraulic occluders were placed around the venae cavae using a previously described technique (9, 11).

Data Collection

Studies were performed after the animals had recovered fully from instrumentation (10 days after original surgery) with the dogs standing and then running on a motorized treadmill (model 1849C; Quinton; Seattle, WA) as previously described (8, 9).

Experimental Protocol

Effects of normal Ex. Steady-state measurements at rest were obtained while the dogs stood on a motorized treadmill. Variably loaded LV P-V loops were generated by sudden, transient occlusion of the venae cavae as previously described (9). The first normal Ex session was then performed with the dogs running on the treadmill. The treadmill speed was gradually increased over 1–2 min from 2.5 mph to the maximum tolerated level of steady-state Ex of 5.5–8.5 mph. The animals exercised at this level until they could no longer keep up with the treadmill. Immediately after steady-state data collection, the treadmill was suddenly stopped and caval occlusions were performed. Data were acquired during 15-s periods throughout the Ex protocol. We analyzed the data recorded during the last minutes of Ex. Because we could not perform caval occlusions during Ex, we assessed LV P-V relations by using caval occlusion data generated immediately after Ex. The total Ex time ranged from 7 to 10 min. After dogs rested for 30 min, a second Ex session was performed. We previously observed that there is no difference in the response to Ex repeated after a 30-min rest period (8, 10). The values of resting controls were also similar before and with a 30-min resting period after Ex.

Induction of CHF. After completion of the baseline studies as previously described (12), rapid right ventricular (RV) pacing (at 220–240 beats/min) was initiated using the pacing protocol. After we employed the pacing protocol for 4–5 wk, when the LV end-diastolic pressure (EDP) during the nonpaced period had increased by >20 mmHg over the prepacing control level, we obtained CHF data.

Effects of CHF Ex. During the stable CHF period, we examined responses to LSM administration. Briefly, before each study, the pacemaker was turned off and the dog was allowed to equilibrate for 1 h. The animal then ran on the treadmill as the speed was increased and adjusted to the maximum tolerated steady-state level, and data were collected while the dog was running. After CHF, the maximum level of Ex was decreased to 3.5–6.0 mph. The total Ex duration was also reduced. After dogs rested for 30 min, LSM was started with loading doses of 24 µg/kg administered for 10 min followed by infusion of LSM at rates of 0.2 µg·kg–1·min–1 for 40 min. When the arterial pressure reached a stable level, steady-state and caval occlusion data were collected and treadmill Ex was performed (10).

The LSM dosing protocol used in this study was identified from a dose-response study. The LSM dosage was chosen to produce a similar increase in LV contractility and a decline in net vascular loading, which was estimated by arterial elastance (Ea) as produced by pimobendan (Pim, 2.5 mg/kg iv) in our past report (41). Briefly, five normal, conscious dogs received LSM loading doses (24 µg/kg for 10 min) followed by infusion at rates of 0.4 µg·kg–1·min–1 for 40 min. End-systolic elastance (Ees) increased by 56% (6.6 ± 1.7 to 10.3 ± 2.1 mmHg/ml), Ea decreased 15% (7.4 ± 1.2 to 6.3 ± 1.1 mmHg/ml), and the time constant of LV relaxation ({tau}) decreased 26% (27.8 ± 3.1 to 20.6.1 ± 3.7 ms; P < 0.05). The alterations in these parameters lasted ~2 h. The LSM doses used in the present study were similar to those used by Pagel et al. (43) in conscious dogs before and after CHF and were also similar to those used in clinical studies of CHF patients (38, 48).

Data Processing and Analysis

As previously described, LV volume, {tau}, the LV end-systolic pressure (ESP)-ESV relation and its slope (Ees), and the stroke work (SW)-end-diastolic volume (EDV) relation and its slope (Msw) were analyzed (9, 10). The {tau} value was analyzed by determining the time constant of the isovolumic decrease of LVP. LVP from the time of peak –dP/dt until mitral valve opening was fit to the exponential equation LVP = PA exp(–t/{tau}) + PB, where t is time and PA, PB, and {tau} are constants determined by the data. Although the decrease in isovolumic pressure is not exactly exponential (58), the time constant, which is derived from the exponential approximation, provides an index of the rate of LV relaxation (17, 34). In addition, {tau} was also calculated by the Weiss method (monoexponential decay model to zero asymptote). As previously described (8, 31), the average LV chamber stiffness value during diastole was obtained by dividing the change in pressure from the time of LVPmin to EDP ({Delta}LVP) by the change of volume during this period. The mean end-systolic circumference stress (WSes, in g/cm2) of the left ventricle was calculated by use of a thick-walled spherical model (51, 52)

where G (1.36) is a conversion factor (from mmHg to g/cm2) and Vm is the LV wall volume (in ml), which is assumed to be 5 ml/kg of body wt (51, 52). Because pacing-induced CHF was previously demonstrated (55) to not alter LV wall mass, we used the same Vm value to calculate WSes both before and after CHF in each animal. LV-arterial coupling was quantitated as the ratio of Ees to Ea and was determined as ESP/stroke volume (SV). The LV P-V area (PVA), which represents the total mechanical energy, was determined as the area under the end-systolic P-V relation and systolic P-V trajectory above the EDP-volume curve. The efficiency of conversion of mechanical energy to external work of the heart was calculated as SW/PVA (39). Ex data were analyzed at two levels: a low speed (2.5 mph) and a high speed (maximum tolerated).

Statistical Analysis

Statistical comparisons were made with Student's t-test for paired observations and ANOVA with the Bonferroni method of multiple-paired comparisons as appropriate. Significance was established as P < 0.05. Data for steady state are expressed as means ± SD; values for LV P-V relations are expressed as means ± SE.

Postmortem Evaluation

At the conclusion of the studies, the animals were killed by lethal injection of pentobarbital sodium (100 mg/kg iv), and the hearts were examined to confirm that instrumentation was properly positioned.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Effects of Pacing-Induced CHF at Rest and During Ex

At rest. As summarized in Table 1 and displayed in Figs. 1 and 2, consistent with our past reports (9, 10), chronic ventricular rapid pacing in a canine model produced progressive LV systolic and diastolic dysfunction. After 4–5 wk of rapid pacing, LV EDP progressively elevated. The ESV and EDV also increased, whereas cardiac output decreased due to a marked reduction of SV (11.2 ± 3.6 vs. 14.8 ± 3.5 ml). Although mean LAP (27.9 ± 4.5 vs. 7.0 ± 1.3 mmHg) was significantly increased, dV/dtmax decreased due to a marked increase in LVPmin (16.5 ± 4.4 vs. 0.9 ± 1.9 mmHg). The {tau} value (35.9 ± 2.9 vs. 27.8 ± 2.4 ms), total systemic resistance, Ea, and LV chamber stiffness values all increased. Mean WSes increased from 65.4 ± 17.8 to 72.4 ± 19.1 g/cm2 (P < 0.05). LV contractility significantly decreased as indicated by significant reductions in the slopes of ESP-ESV (Ees: 47%; 6.7 ± 1.8 vs. 3.5 ± 0.4 mmHg/ml), dP/dtmax-EDV (dE/dtmax: 45%; 71.0 ± 11.2 vs. 38.6 ± 6.4 mmHg·s–1·ml–1), and SW-EDV (Msw: 40%; 80.4 ± 7.8 vs. 50.1 ± 4.5 mmHg) relations (Table 2). The Ees/Ea ratio decreased from 0.89 ± 0.31 to 0.47 ± 0.05, and LV mechanical efficiency, measured as SW/PVA, decreased from 0.63 ± 0.07 to 0.54 ± 0.09 (Table 3).


View this table:
[in this window]
[in a new window]
  		Table 1. Effects of levosimendan on steady-state hemodynamics before and after CHF

 


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1. Left ventricular (LV) pressure-volume (P-V) loops obtained from one animal at rest (A) and during exercise (Ex; B) before and after congestive heart failure (CHF). Each loop was generated by averaging the data obtained during a 15-s recording period that spanned several respiratory cycles. During normal Ex, the early diastolic portion of the LV P-V loop was shifted downward so that the early diastolic LV pressure (LVP) was lower during Ex than at rest. However, after CHF, the early diastolic portion of the LV P-V loop was shifted upward during Ex so that early diastolic LVP was much higher.

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 2. LV P-V loops and P-V relations determined from a conscious dog after CHF and before and after administration of levosimendan (LSM). Treatment with LSM produced leftward shifts of the LV end-systolic pressure (ESP)-end-systolic volume (ESV; A), dP/dtmax-end-diastolic volume (VED; B), and stroke work-end-diastolic volume (C) relations with increased slopes. This indicates that LSM increased LV contractility after CHF.

 

View this table:
[in this window]
[in a new window]
  		Table 2. Effects of levosimendan on LV pressure-volume relations after CHF

 

View this table:
[in this window]
[in a new window]
  		Table 3. Effects of levosimendan on Ees/Ea, stroke work, and work efficiency after CHF

 
During Ex. After CHF, the duration of Ex was reduced to 4.5 ± 1.9 min, and the speed of Ex decreased to 3.5–5.3 mph. As shown in Fig. 1 and Table 1, consistent with our previous observations (7, 8), normal Ex caused an improvement in LV diastolic performance with a decreased {tau} (21.5 ± 2.1 vs. 27.8 ± 2.4 ms), a lower LVPmin, and an increased dV/dtmax (247 ± 49 vs. 184 ± 59 ml/s) without an increase in LAP (7.6 ± 1.2 vs. 7.0 ± 1.3 mmHg). The early diastolic portion of the LV P-V loop was shifted downward so that LVP was lower throughout early and mid-diastole during Ex than at rest (Fig. 1A). In contrast with the findings during Ex before CHF, {tau} (40.4 ± 5.3 vs. 35.9 ± 2.9 ms), LV EDP, LVPmin (21.9 ± 3.1 vs. 16.5 ± 4.4 mmHg), and mean LAP (33.7 ± 3.9 vs. 27.9 ± 4.5 mmHg) all increased during Ex after CHF. As shown in Figs. 1B and 2, these changes were accompanied by a consistent rightward and upward shift of the early diastolic portion of the LV P-V loop. During early diastole, at an equivalent LV volume, LVP was significantly higher during Ex than at rest after CHF. Thus any diastolic dysfunction present at rest in CHF is exacerbated during Ex (8, 11). As summarized in Table 3, before CHF, the Ees/Ea ratio was 0.89 ± 0.31 and increased to 1.27 ± 0.21 during Ex. Thus SW/PVA was improved from 0.63 ± 0.07 to 0.69 ± 0.09 during normal Ex. In contrast, after severe CHF, the Ees/Ea ratio significantly decreased to 0.47 ± 0.05 and further decreased to 0.41 ± 0.03 during CHF Ex, which led to a significant reduction in SW/PVA (0.51 ± 0.06 vs. 0.54 ± 0.09).

Effects of LSM After CHF at Rest and During Ex

At rest. As summarized in Table 1 and displayed in Figs. 2 and 3, compared with CHF at rest, LSM produced no changes in heart rate and rhythm. LSM significantly reduced resting LV Ea (6.1 ± 1.2 vs. 7.7 ± 1.3 mmHg/ml), EDP (26.7 ± 3.2 vs. 32.5 ± 3.0 mmHg), and mean LAP (22.7 ± 3.9 vs. 27.9 ± 4.5 mmHg; P < 0.05). The peak mitral flow (dV/dtmax, 217 ± 59 vs. 129 ± 49 mmHg/s) was increased due to decreased LVPmin (11.4 ± 4.8 vs. 16.5 ± 4.4 mmHg) and {tau} (30.8 ± 2.2 vs. 35.9 ± 2.9 ms). SV (14.7 ± 3.6 vs. 11.2 ± 3.6 ml) and cardiac output increased dramatically. Both LV chamber stiffness (1.08 ± 0.22 vs. 1.48 ± 0.28 mmHg/ml) and WSes were significantly reduced. The slopes of LV P-V relations were increased (Ees, 62%; dE/dtmax, 54%; MSW, 39%; see Table 2 and Fig. 2). Ees/Ea was increased from 0.47 ± 0.05 to 0.85 ± 0.07. Mechanical efficiency, measured as SW/PVA, was also significantly improved (0.61 ± 0.07 vs. 0.54 ± 0.09; see Table 3).



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 3. Steady-state LV P-V loops obtained from one animal after CHF at rest and during Ex with and without LSM treatment. After CHF, the early diastolic portion of the LV P-V loop was shifted upward during Ex so that the early diastolic LVP was increased during Ex after CHF. After treatment with LSM, Ex produced a greater stroke volume and the abnormal Ex response was restored to the normal downward shift during Ex so that early diastolic LVP did not increase but decreased with Ex after CHF.

 
During Ex. Compared with CHF Ex without treatment, LSM treatment significantly attenuated the Ex-induced increase in LV ESP and reversed Ex-induced abnormal increases in LVPmin, {tau}, and the upward shift of the early diastolic portion of the LV P-V loop (see Figs. 2, 4, and 5 and Table 1). As demonstrated in Fig. 4, during CHF Ex without LSM treatment, increased levels of Ex revealed adverse actions with a further decreased rate of LV relaxation and reduced LV contractility as measured by Msw. LSM treatment completely reversed these abnormal responses. Treatment with LSM and increased levels of Ex caused a further augmented rate of LV relaxation and Msw. Compared with CHF controls, after LSM treatment, CHF Ex caused a downward shift of the diastolic portion of LV P-V loops. The dV/dtmax ({Delta} = 83 ± 26 ml/s) value was additionally augmented due to significant decreases in {tau} ({Delta} = 4.5 ± 2.1 ms) and LVPmin ({Delta} = 5.8 ± 1.6 mmHg) without an abnormal increase in mean LAP. In addition, during CHF Ex after treatment with LSM, Ees/Ea increased, which resulted from a significantly increased Ees but relatively unchanged Ea. Thus with LSM treatment, CHF Ex further improved the SW/PVA value to 0.67 ± 0.07, which is close to the values of normal controls before CHF at rest and during Ex (see Fig. 5 and Table 3). With LSM treatment, the duration of Ex was also significantly increased (4.5 ± 1.9 vs. 7.5 ± 1.5 min; P < 0.05).



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 4. Effects of graded levels of CHF Ex with and without LSM on the time constant (A) of LV relaxation and contractile function measured by the slope of the LV stroke work (SW)-end-diastolic volume relation (Msw; B). During CHF Ex without LSM treatment (control), increased levels of Ex showed adverse actions with further depressed rates of LV relaxation and contractility. Treatment with LSM completely reversed these abnormal responses. With LSM treatment, increased levels of Ex caused further augmented rates of LV relaxation and contractility. Values are group means ± SD.

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 5. Differences between CHF Ex and CHF at rest on LV filling (A) and LV arterial coupling and SW/P-V area (PVA; B) with and without LSM treatment. Compared with CHF at rest, CHF Ex caused an increase in maximum mitral peak filling rate (dV/dtmax) due to significant increases in mean left atrial pressure (LAP), whereas the time constant of LV relaxation ({tau}) and minimum LVP values were increased. In contrast, during CHF Ex with LSM treatment, there were decreases in {tau}, mean LAP, and minimum LVP with a greater increase in dV/dtmax. During CHF Ex, the ratio of end-systolic elastance (Ees) to arterial elastance (Ea) decreased resulting from a significantly increased Ea but a relatively unchanged Ees, which led to a reduction in SW/PVA. In contrast, LSM reversed the CHF Ex-induced abnormal responses and caused significant increases in Ees/Ea and SW/PVA values. Values are group means ± SD.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
We investigated the effects of LSM, a new Ca2+ sensitizer, on LV systolic and diastolic function at rest and during Ex in an animal model of CHF that mimics many of the functional and neurohormonal changes of clinical CHF (5, 10, 23, 50). We found that after CHF, at rest, a clinically relevant dose of LSM produces arterial vasodilatation, improves LV relaxation and diastolic filling, and increases contractility, LV arterial coupling, and mechanical efficiency. Importantly, the effects of treatment with LSM persisted during Ex after CHF. Treatment with LSM prevents CHF Ex-induced abnormal increases in early diastolic LVP and mean LAP and restores the normal Ex response.

CHF is associated with progressive sympathetic nervous system activation but diminished inotropic response to {beta}-adrenergic receptor stimulation in part due to a selective downregulation of {beta}1-adrenergic receptors and upregulation of the inhibitory G protein Gi. The net effect of these alterations is a substantial blunting of the {beta}-adrenergic receptor-mediated cardiac response with clinical consequences of a decline in myocardial reserve (4, 5, 46) and an impairment in Ex response (8, 11). Consistently, in the present study, the conscious dogs with pacing-induced CHF exhibited progressive LV systolic and diastolic dysfunction and abnormal LV function during Ex. We found that in CHF, the impaired LV arterial coupling and diastolic dysfunction present at rest are exacerbated during Ex. During CHF Ex, there is a reversal of the normal Ex-induced augmentation of LV relaxation and a decrease in early diastolic LVP with a resulting increase in LAP. We and others reported earlier (9, 45) that abnormal Ex response is attributable to several factors such as impaired intrinsic contractility, blunted inotropic responses to {beta}-adrenoceptor agonists, enhanced sensitivity of LV relaxation to Ex-induced increased systolic load, high levels of ANG II and endothelin-1 (10), altered force-frequency relation (40), and a blunted peripheral arterial vasodilator response to Ex.

LSM, which is a pyridazinone-dinitrile derivative, is reportedly an inotropic and vasodilator agent without adverse effects on diastolic function. In this study, we found that in conscious dogs with pacing-induced CHF, LSM produced a marked increase in LV contractility and improved LV relaxation both at rest and during Ex. Treatment with LSM also caused favorable reductions in LV EDP, total systemic resistance, Ea, and LV stiffness without changing heart rate. Moreover, after CHF, LSM treatment prevented Ex-induced increases in EDP and mean LAP. With LSM, there was a normal enhancement of LV relaxation and a decrease in early LV diastolic pressure that occurred during Ex.

These hemodynamic beneficial effects result from the positive inotropic action of LSM and a reduction in systolic load. The mechanism of the positive inotropic action of LSM is not entirely clear. Unlike most other myofilament Ca2+ sensitizers, the inotropic effect of LSM is partly mediated by Ca2+ concentration-dependent conformational changes in troponin C that lead to sensitization of the contractile apparatus to Ca2+ ions during systole (20, 21). At high LSM concentrations, phosphodiesterase III inhibition may play some role in the positive inotropic effects (13). However, LSM was reported to be a cardiotonic agent with Ca2+-sensitizing and -mobilizing actions over identical concentration ranges (14, 47). Increases in the activity of the Na+/Ca2+ exchanger with LSM may also contribute to improved relaxation (25). LSM-induced vasodilatation is likely mediated by the opening of ATP-dependent K+ channels in vascular smooth muscle (29, 59, 60).

LSM improved systolic function without impairing relaxation and also improved relaxation during Ex. Previously, we found an impaired LV systolic and diastolic force-frequency relation and an adverse effect of tachycardia on LV arterial coupling and mechanical efficiency in conscious dogs with pacing-induced CHF (40). Treatment with LSM has been shown to improve frequency-induced force generation in human failing myocardium (25) and convert a negative force-frequency relationship into a positive relationship (6, 27). Thus an LSM reversal of the negative force-frequency relationship may have contributed to the beneficial effects of LSM that we observed during CHF Ex.

Previous observations in our laboratory have demonstrated that normally functioning LV and arterial systems are nearly optimally coupled to produce SW both at rest and during Ex (30). In the present study, we found that during the development of CHF, the Ees/Ea ratio was reduced, which resulted in less than maximal SW. Furthermore, this coupling ratio was additionally depressed during Ex, thus contributing to Ex intolerance in CHF. Treatment with LSM significantly reduced LV wall stress and caused an increase in the Ees/Ea ratio with resulting nearly maximum SW both at rest and during Ex after CHF. Thus with LSM, LV mechanical efficiency was significantly augmented in CHF both at rest and during Ex. This finding is consistent with recent clinical observations that LSM induces enhanced contractility without increasing myocardial oxygen demand (54, 57) and induction of arrhythmias (15, 38).

The upward shift in the early diastolic portion of the LV P-V loop that we observed during CHF Ex is similar to that reported by Miyazaki et al. (34) in exercising dogs with coronary stenosis as well as that found in clinical studies of Ex-induced ischemia (33, 53). In these studies, the decrease in LV distensibility during Ex was due to the effect of myocardial ischemia. Although our animals did not have coronary stenosis, Ex-induced ischemia may have contributed to our findings. Thus LSM caused coronary vasodilatation (29) and may have contributed to improved LV relaxation and filling during Ex after CHF.

LSM appears to have some advantages over other positive inotropic agents. Although {beta}-adrenergic stimulation improves contraction and relaxation, its effects are reduced after CHF (11, 49, 56). Furthermore, we found that compared with CHF at rest, LSM was more effective than Pim in producing decreases in LVPmin, ESV, and {tau} during CHF Ex. Ex duration in CHF was increased only by LSM. Treatment with LSM also reversed the CHF Ex-induced decrease in cardiac efficiency. These findings support a previous report that Pim has only weak Ca2+-sensitizing effects (2, 3, 16, 41). It has been shown that as a Ca2+-sensitizing agent, treatment with LSM is ~100 times more potent than Pim (21).

In recent clinical trials, intravenous administration of LSM produced dose-dependent favorable hemodynamic effects in the acute treatment of stable or decompensated CHF (38, 48). Furthermore, LSM improved the survival of patients with severe low-output CHF compared with dobutamine (15). In addition, LSM reduced worsening CHF and death in patients with CHF complicating acute myocardial infarction (35). The present findings and clinical observations are consistent with the known pharmacological actions of the drug as a Ca2+ sensitizer and direct vasodilator (14, 20, 21, 25, 48).

Several methodological issues should be considered in the interpretation of our data. First, although we studied an animal model of CHF (pacing tachycardia) that reproduces many of the functional and neurohormonal features of clinical CHF, this experimental model demonstrated biventricular chamber dilatation with increased LV and RV filling pressures and striking abnormalities in systolic and diastolic function similar to those found in patients with dilated congestive cardiomyopathy (1, 5, 8, 9, 28, 32, 43, 45, 49). We cannot be certain that our results apply to CHF of other causes such as hypertropic cardiomyopathy.

Second, we studied the acute effects of LSM treatment. We do not know the effects of prolonged treatment with LSM.

Third, the use of a simple exponential to characterize relaxation is an approximation, because LV isovolumic pressure does not decay exactly exponentially. Yellin et al. (58) evaluated the validity of a monoexponential characterization of relaxation and revealed that late relaxation is more rapid than predicted by a monoexponential relation. However, when {tau} is calculated from a filling cycle by assuming a zero-pressure asymptote (i.e., the conventional way), there is no significant difference with the true value based on the nonfilling cycle (17, 58). The monoexponential {tau} remains a useful index of relaxation and correlates well with other temporal indexes (isovolumic relaxation time and relaxation half-time (17, 58).

In conclusion, after CHF, a clinically relevant dose of LSM produces arterial vasodilatation; improves LV relaxation and diastolic filling; increases contractility, LV arterial coupling, and mechanical efficiency; and restores normal Ex response. The present study supports the view that LSM may be the first inotropic agent that is both safe and effective in altering clinical outcomes such as mortality and poor Ex tolerance for patients with CHF.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported in part by Grants HL-53541, AA-12335, and HL-074318 from the National Institutes of Health and 9640189N from the American Heart Association.


   ACKNOWLEDGMENTS
 
The authors acknowledge the computer programming of Dr. Ping Tan, the technical assistance of Michael Cross and Mack Williams, and the secretarial assistance of Amanda Burnette.


   FOOTNOTES
 

Address for reprint requests and other correspondence: C.-P. Cheng, Section on Cardiology, Wake Forest Univ. School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1045 (E-mail: ccheng{at}wfubmc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Armstrong PW, Stopps TP, Ford SE, and DeBold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 74: 1075–1084, 1986.[Abstract/Free Full Text]
  2. Asanoi H, Ishizaka S, Kameyama T, Ishise H, and Sasayama S. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 23: 268–274, 1994.[ISI][Medline]
  3. Bohm M, Morano I, Pieske B, Ruegg JC, Wankerl M, Zimmermann R, and Erdmann E. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689–701, 1991.[Abstract/Free Full Text]
  4. Braunwald E and Bristow MR. Congestive heart failure: fifty years of progress. Circulation 102: IV-14–IV-23, 2000.
  5. Bristow MR. (beta)-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569, 2000.[Free Full Text]
  6. Brixius K, Reicke S, and Schwinger RH. Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 282: H131–H137, 2002.[Abstract/Free Full Text]
  7. Cheng CP, Igarashi Y, and Little WC. Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 70: 9–19, 1992.[Abstract/Free Full Text]
  8. Cheng CP, Noda T, Nozawa T, and Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 72: 795–806, 1993.[Abstract/Free Full Text]
  9. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, and Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78: 880–892, 1996.[Abstract/Free Full Text]
  10. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, and Little WC. The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280: H1853–H1860, 2001.[Abstract/Free Full Text]
  11. Cheng HJ, Han QH, Morimoto A, Hasegawa H, Cross M, Zhang C, and Cheng CP. Beta 3-adrenergic receptor activation contributes to exercise intolerance in heart failure (Abstract). Circulation 110: III-432, 2004.
  12. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, and Cheng CP. Upregulation of functional (beta)3-adrenergic receptor in the failing canine myocardium. Circ Res 89: 599–606, 2001.[Abstract/Free Full Text]
  13. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, and Solaro RJ. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107–113, 1995.[Abstract/Free Full Text]
  14. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40: 323–338, 2002.[CrossRef][ISI][Medline]
  15. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, and Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): a randomised double-blind trial. Lancet 360: 196–202, 2002.[CrossRef][ISI][Medline]
  16. Fujino K, Sperelakis N, and Solaro RJ. Differential effects of D- and L-pimobendan on cardiac myofilament calcium sensitivity. J Pharmacol Exp Ther 247: 519–523, 1988.[Abstract/Free Full Text]
  17. Gilbert JC and Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relations. Circ Res 64: 827–852, 1989.[Free Full Text]
  18. Grossman W. Blood flow measurement: the cardiac output. In: Cardiac Catheterization, Angiography and Intervention, edited by Grossman W and Baim DS. Philadelphia, PA: Lea & Febiger, 1990, p. 105–122.
  19. Haikala H, Levojoki J, and Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 27: 2155–2165, 1995.[CrossRef][ISI][Medline]
  20. Haikala H and Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26, Suppl 1: S10–S19, 1995.
  21. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, and Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794–801, 1995.[ISI][Medline]
  22. Hajjar RJ, Schmidt U, Helm P, and Gwathmey JK. Ca2+ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 280: 247–254, 1997.[Abstract/Free Full Text]
  23. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Guillaume P, Olivari MT, and Thomas S. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99: 990–992, 1999.[Abstract/Free Full Text]
  24. Harkin CP, Pagel PS, Tessmer JP, and Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 26: 179–188, 1995.[ISI][Medline]
  25. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, and Just H. Influence of the novel inotropic agent, levosimendan, on isometric tension and calcium cycling in failing human myocardium. Circulation 98: 2141–2147, 1998.[Abstract/Free Full Text]
  26. Higashiyama A, Watkins MW, Chen Z, and LeWinter MM. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 92: 3094–3104, 1995.[Abstract/Free Full Text]
  27. Janssen PM, Datz N, Zeitz O, and Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404: 191–199, 2000.[CrossRef][ISI][Medline]
  28. Johnson RA and Palacios I. Dilated cardiomyopathies of the adult. N Engl J Med 307: 1051–1058, 1982.[ISI][Medline]
  29. Kaheinen P, Pollesello P, Levijoki J, and Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37: 367–374, 2001.[CrossRef][ISI][Medline]
  30. Little WC and Cheng CP. Coupling of the left ventricular and arterial system. Med Biol Eng Comput 32: 205–209, 1994.[ISI][Medline]
  31. Little WC, Ohno M, Kitzman DW, Thomas JD, and Cheng CP. Determination of left ventricular chamber stiffness from the time for deceleration of early left ventricular filling. Circulation 92: 1933–1939, 1995.[Abstract/Free Full Text]
  32. Lohse MJ, Engelhardt S, and Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 93: 896–906, 2003.[Abstract/Free Full Text]
  33. Mirsky I, Corin WJ, Murakami T, Grimm J, Hess OM, and Krayenbuehl HP. Correction for preload in assessment of myocardial contractility in aortic and mitral valve disease. Application of the concept of systolic myocardial stiffness. Circulation 78: 68–80, 1988.[Abstract/Free Full Text]
  34. Miyazaki S, Guth BD, Miura T, Indolfi C, Schulz R, and Ross J Jr. Changes of left ventricular diastolic function in exercising dogs without and with ischemia. Circulation 81: 1058–1070, 1990.[Abstract/Free Full Text]
  35. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI: RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422–1432, 2002.[Abstract/Free Full Text]
  36. Myers J, Prakash M, Froelicher V, Partington S, and Atwood E. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346: 793–801, 2002.[Abstract/Free Full Text]
  37. Narang R, Swedberg K, and Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Eur Heart J 17: 120–134, 1996.[Abstract/Free Full Text]
  38. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, and Remme WJ. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36: 1903–1912, 2000.[Abstract/Free Full Text]
  39. Nozawa T, Cheng CP, Noda T, and Little WC. Effect of exercise on left ventricular mechanical efficiency in conscious dogs. Circulation 90: 3047–3054, 1994.[Abstract/Free Full Text]
  40. Ohte N, Cheng CP, and Little WC. Tachycardia exacerbates abnormal left ventricular-arterial coupling in heart failure. Heart Vessels 18: 136–141, 2003.[CrossRef][ISI][Medline]
  41. Ohte N, Cheng CP, Suzuki M, and Little WC. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 282: 23–31, 1997.[Abstract/Free Full Text]
  42. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, and DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468–1475, 1991.[Abstract]
  43. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, and Warltier DC. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 29: 563–573, 1997.[CrossRef][ISI][Medline]
  44. Piepoli MF, Davos C, Francis DP, Coats AJS, Belardinelli R, Purcaro A, and the ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). Br Med J 328: 1–7, 2004.[Abstract/Free Full Text]
  45. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JL, Myers JN, and Sullivan MJ. Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation 107: 1210–1225, 2003.[Free Full Text]
  46. Post SR, Hammond HK, and Insel PA. Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 39: 343–360, 1999.[CrossRef][ISI][Medline]
  47. Sato S, Talukder MAH, Sugawara H, and Sawada H. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30: 1115–1128, 1998.[CrossRef][ISI][Medline]
  48. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, and Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102: 2222–2227, 2000.[Abstract/Free Full Text]
  49. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Brown R, Vacchiano CA, and Zile MR. Cellular and molecular alterations in the beta-adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 28: 1243–1250, 1994.[Abstract/Free Full Text]
  50. Spinale FG, Walker JD, Mukherjee R, Lannini JP, Keever AT, and Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 95: 1918–1929, 1997.[Abstract/Free Full Text]
  51. Suga H, Kitabatake A, and Sagawa K. End-systolic pressure determines stroke volume from fixed end-diastolic volume in the isolated canine left ventricle under a constant contractile state. Circ Res 44: 238–249, 1979.[Free Full Text]
  52. Suga H and Sagawa K. Graphical estimation of ventricular wall force and stress from pressure-volume diagram. Am J Physiol Heart Circ Physiol 236: H787–H789, 1979.[Abstract/Free Full Text]
  53. Tebbe U, Scholz H, Kreuzer H, and Neuhaus KL. Changes in left ventricular diastolic function during exercise in patients with coronary artery disease. Eur Heart J 8: 21–28, 1987.
  54. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, and Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279: 120–127, 1996.[Abstract/Free Full Text]
  55. Tomita M, Spinale FG, Crawford FA, and Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy: disparity between recovery of systolic versus diastolic function. Circulation 83: 635–644, 1991.[Abstract/Free Full Text]
  56. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, and Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 103: 750–755, 2001.[Abstract/Free Full Text]
  57. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, and Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68: 522–531, 2000.[CrossRef][ISI][Medline]
  58. Yellin EL, Hori M, Yoran C, Sonnenblick EH, Gabbay S, and Frater RW. Left ventricular relaxation in the filling and nonfilling intact canine heart. Am J Physiol Heart Circ Physiol 250: H620–H629, 1986.[Abstract/Free Full Text]
  59. Yokoshiki H, Katsube Y, Sunagawa M, and Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333: 249–259, 1997.[CrossRef][ISI][Medline]
  60. Yokoshiki H, Katsube Y, Sunagawa M, and Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375–383, 1997.[Abstract/Free Full Text]
  61. Zairis MN. CASINO results: should docs gamble on levosimendan? Heartwire, March 9, 2004; www.theheart.org.
  62. Zairis MN, Apostolatos C, Anastasiadis P, Mytas D, Katsaris C, Kouris N, Grassos H, Karidis K, Adamopoulou E, Argyrakis S, Prekates A, and Foussas S. The effect of a calcium sensitizer or an inotrope or none in chronic low-output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO) (Abstract). J Am Coll Cardiol 43, Suppl A: 206A, 2004.
  63. Ziesche S, Cobb FR, Cohn JN, Johnson G, and Tristani F. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure: results from V-HeFT and V-HeFT II: the HeFT VA Cooperative Studies Group. Circulation 87, Suppl 6: VI-56–VI-64, 1993.
  64. Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, and Scholz H. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur J Cardiothorac Surg 14: 70–75, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. Masutani, H.-J. Cheng, M. Hyttila-Hopponen, J. Levijoki, A. Heikkila, A. Vuorela, W. C. Little, and C.-P. Cheng
Orally Available Levosimendan Dose-Related Positive Inotropic and Lusitropic Effect in Conscious Chronically Instrumented Normal and Heart Failure Dogs
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 236 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. S. Pagel
Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application?
Anesth. Analg., April 1, 2007; 104(4): 759 - 761.
[Full Text] [PDF]

Home page
 CirculationHome page
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci
Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships
Circulation, March 13, 2007; 115(10): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. A. Zager, A. C. Johnson, S. Lund, S. Y. Hanson, and C. K. Abrass
Levosimendan protects against experimental endotoxemic acute renal failure
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1453 - F1462.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Steendijk, S. A. Tulner, J. J. Bax, P. V. Oemrawsingh, G. B. Bleeker, L. van Erven, H. Putter, H. F. Verwey, E. E. van der Wall, and M. J. Schalij
Hemodynamic Effects of Long-Term Cardiac Resynchronization Therapy: Analysis by Pressure-Volume Loops
Circulation, March 14, 2006; 113(10): 1295 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. A. Kass and R. J. Solaro
Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart
Circulation, January 17, 2006; 113(2): 305 - 315.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. E. Montgomery, V. L. M. Rundell, P. H. Goldspink, D. Urboniene, D. L. Geenen, P. P. de Tombe, and P. M. Buttrick
Protein kinase C{varepsilon} induces systolic cardiac failure marked by exhausted inotropic reserve and intact Frank-Starling mechanism
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1881 - H1888.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Dernellis and M. Panaretou
Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: A Combined Hemodynamic and Doppler Echocardiographic Study
Chest, October 1, 2005; 128(4): 2633 - 2639.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H914    most recent
00465.2004v1